AbCellera Inks Jazz Pharma Deal: $56M Upfront, Potential $792M Per Program in Milestones
ABCL sits 87% above its 52-week low of $2.745.
Summary
AbCellera announced a significant collaboration with Jazz Pharmaceuticals to discover next-generation T-cell engaging multispecific antibodies for various cancers. AbCellera will receive $56 million upfront for two initial programs, with an additional $28 million due upon starting a third. Critically, the deal includes potential milestone payments of up to $792 million per program plus tiered royalties, offering substantial long-term revenue upside. This partnership provides immediate financial strength and validates AbCellera's discovery platform, materially de-risking its pipeline.
At the time of this announcement, ABCL was trading at $5.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $2.75 to $6.79. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: PR Newswire.